Dr. Umakanta Sahoo, Managing Director, GCT — India, a Global Clinical Trials, LLC company, participates in a 2 days Conference at Courtyard Marriott, Mumbai, organised by the DIA on topic «Deciphering the Why, When and How of Risk Based Monitoring.» Please visit this page to find out more about the Conference.
With the changes in ICHE6 R2 guidance, India is getting ready to join its western counterparts to focus on developing RBM strategies. The Indian industry has felt an urgent need to understand the strategies involved in RBM, including the development of the IQRMP, the development of a risk scoring model, the identification of the KRIs, the SDV strategy, the site-tiering strategy, the road-blocks and the pre-emptive measures, the identification of the proof points and the latest regulations and the tools and technologies involved. The day 1 unfolded well with good meaningful discussions.
GCT offers CRO services in EU, Russia and India and has accumulated strong background across the wide range of therapeutic areas. If you plan to participate at the DIA Conference tomorrow, we invite you to meet with Dr. Sahoo and discuss your pre-clinical and clinical development plans and the possibility of introducing your products to the foreign markets. Otherwise, please contact bd@gctrials.com.